The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia

Seminars in Cancer Biology

Volumn 20, Issue 6, 2010, Pages 391-399

  Packham, Graham ^a   Stevenson, Freda ^b  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Anergy; B cell receptor; Chronic lymphocytic leukaemia; Signalling

Indexed keywords

B LYMPHOCYTE RECEPTOR; BIM PROTEIN; CD79A ANTIGEN; CD79B ANTIGEN; DASATINIB; FOSTAMATINIB; IMMUNOGLOBULIN M; LYMPHOCYTE MEMBRANE IMMUNOGLOBULIN; PROTEIN BCL 2; PROTEIN KINASE C BETA; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; T CELL LEUKEMIA 1 PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY REACTION; B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CANCER SURVIVAL; CELL CYCLE; CELL FUNCTION; CELL MATURATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG RESEARCH; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; NONHUMAN; PROTEIN GLYCOSYLATION; REVIEW; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ANIMALS; HUMANS; IMMUNOGLOBULINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, ANTIGEN, B-CELL; SIGNAL TRANSDUCTION;

EID: 78649792807     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2010.08.004     Document Type: Review

References (102)

1. Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
2. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
3. Tolar P., Sohn H.W., Liu W., Pierce S.K. The molecular assembly and organization of signaling active B-cell receptor oligomers. Immunol Rev 2009, 232:34-41.
4. Liu W., Meckel T., Tolar P., Sohn H.W., Pierce S.K. Antigen affinity discrimination is an intrinsic function of the B cell receptor. J Exp Med 2010, 207:1095-1111.
5. Treanor B., Harwood N.E., Batista F.D. Microsignalosomes: spatially resolved receptor signalling. Biochem Soc Trans 2009, 37:1014-1018.
6. Depoil D., Fleire S., Treanor B.L., Weber M., Harwood N.E., Marchbank K.L., et al. CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand. Nat Immunol 2008, 9:63-72.
7. Damle R.N., Ghiotto F., Valetto A., Albesiano E., Fais F., Yan X.J., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002, 99:4087-4093.
8. Mockridge C.I., Potter K.N., Wheatley I., Neville L.A., Packham G., Stevenson F.K. Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. Blood 2007, 109:4424-4431.
9. Herve M., Xu K., Ng Y.S., Wardemann H., Albesiano E., Messmer B.T., et al. Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 2005, 115:1636-1643.
10. Lanemo Myhrinder A., Hellqvist E., Sidorova E., Soderberg A., Baxendale H., Dahle C., et al. A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. Blood 2008, 111:3838-3848.
11. Klein U., Tu Y., Stolovitzky G.A., Mattioli M., Cattoretti G., Husson H., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001, 194:1625-1638.
12. Johnson T.A., Rassenti L.Z., Kipps T.J. Ig VH1 genes expressed in B cell chronic lymphocytic leukemia exhibit distinctive molecular features. J Immunol 1997, 158:235-246.
13. Stamatopoulos K., Belessi C., Moreno C., Boudjograh M., Guida G., Smilevska T., et al. Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: pathogenetic implications and clinical correlations. Blood 2007, 109:259-270.
14. Messmer B.T., Raphael B.J., Aerni S.J., Widhopf G.F., Rassenti L.Z., Gribben J.G., et al. Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. Leuk Res 2009, 33:368-376.
15. Kipps T.J., Tomhave E., Pratt L.F., Duffy S., Chen P.P., Carson D.A. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1989, 86:5913-5917.
16. Forconi F., Potter K.N., Wheatley I., Darzentas N., Sozzi E., Stamatopoulos K., et al. The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010, 115:71-77.
17. Tobin G., Thunberg U., Karlsson K., Murray F., Laurell A., Willander K., et al. Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. Blood 2004, 104:2879-2885.
18. Thorpe S.J., Boult C.E., Stevenson F.K., Scott M.L., Sutherland J., Spellerberg M.B., et al. Cold agglutinin activity is common among human monoclonal IgM Rh system antibodies using the V4-34 heavy chain variable gene segment. Transfusion 1997, 37:1111-1116.
19. Dal-Bo M., Bertoni F., Forconi F., Zucchetto A., Bomben R., Marasca R., et al. Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. J Transl Med 2009, 7:76.
20. Lanham S., Hamblin T., Oscier D., Ibbotson R., Stevenson F., Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood 2003, 101:1087-1093.
21. Guarini A., Chiaretti S., Tavolaro S., Maggio R., Peragine N., Citarella F., et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. Blood 2008, 112:782-792.
22. Chen L., Widhopf G., Huynh L., Rassenti L., Rai K.R., Weiss A., et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002, 100:4609-4614.
23. Zupo S., Isnardi L., Megna M., Massara R., Malavasi F., Dono M., et al. CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. Blood 1996, 88:1365-1374.
24. Deglesne P.A., Chevallier N., Letestu R., Baran-Marszak F., Beitar T., Salanoubat C., et al. Survival response to B-cell receptor ligation is restricted to progressive chronic lymphocytic leukemia cells irrespective of Zap70 expression. Cancer Res 2006, 66:7158-7166.
25. Stevenson F.K., Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood 2004, 103:4389-4395.
26. Cambier J.C., Gauld S.B., Merrell K.T., Vilen B.J. B-cell anergy: from transgenic models to naturally occurring anergic B cells?. Nat Rev Immunol 2007, 7:633-643.
27. Brink R., Goodnow C.C., Crosbie J., Adams E., Eris J., Mason D.Y., et al. Immunoglobulin M and D antigen receptors are both capable of mediating B lymphocyte activation, deletion, or anergy after interaction with specific antigen. J Exp Med 1992, 176:991-1005.
28. Niiro H., Clark E.A. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002, 2:945-956.
29. Dal Porto J.M., Gauld S.B., Merrell K.T., Mills D., Pugh-Bernard A.E., Cambier J. B cell antigen receptor signaling 101. Mol Immunol 2004, 41:599-613.
30. Kulathu Y., Hobeika E., Turchinovich G., Reth M. The kinase Syk as an adaptor controlling sustained calcium signalling and B-cell development. EMBO J 2008, 27:1333-1344.
31. Geahlen R.L. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim Biophys Acta 2009, 1793:1115-1127.
32. Jiang A., Craxton A., Kurosaki T., Clark E.A. Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 1998, 188:1297-1306.
33. Takata M., Sabe H., Hata A., Inazu T., Homma Y., Nukada T., et al. Tyrosine kinases Lyn and Syk regulate B cell receptor-coupled Ca2+ mobilization through distinct pathways. EMBO J 1994, 13:1341-1349.
34. Hashimoto A., Okada H., Jiang A., Kurosaki M., Greenberg S., Clark E.A., et al. Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med 1998, 188:1287-1295.
35. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004, 15:177-182.
36. Healy J.I., Dolmetsch R.E., Timmerman L.A., Cyster J.G., Thomas M.L., Crabtree G.R., et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997, 6:419-428.
37. Nedellec S., Renaudineau Y., Bordron A., Berthou C., Porakishvili N., Lydyard P.M., et al. B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. J Immunol 2005, 174:3749-3756.
38. Allsup D.J., Kamiguti A.S., Lin K., Sherrington P.D., Matrai Z., Slupsky J.R., et al. B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. Cancer Res 2005, 65:7328-7337.
39. Vallat L.D., Park Y., Li C., Gribben J.G. Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. Blood 2007, 109:3989-3997.
40. Barragan M., De Frias M., Iglesias-Serret D., Campas C., Castano E., Santidrian A.F., et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase C{beta}. J Leukoc Biol 2006, 80:1473-1479.
41. Kawauchi K., Ogasawara T., Yasuyama M. Activation of extracellular signal-regulated kinase through B-cell antigen receptor in B-cell chronic lymphocytic leukemia. Int J Hematol 2002, 75:508-513.
42. Petlickovski A., Laurenti L., Li X., Marietti S., Chiusolo P., Sica S., et al. Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 2005, 105:4820-4827.
43. Bernal A., Pastore R.D., Asgary Z., Keller S.A., Cesarman E., Liou H.C., et al. Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 2001, 98:3050-3057.
44. Rodriguez A., Martinez N., Camacho F.I., Ruiz-Ballesteros E., Algara P., Garcia J.F., et al. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. Clin Cancer Res 2004, 10:6796-6806.
45. Herreros B., Rodriguez-Pinilla S.M., Pajares R., Martinez-Gonzalez M.A., Ramos R., Munoz I., et al. Proliferation centers in chronic lymphocytic leukemia: the niche where NF-kappaB activation takes place. Leukemia 2010, 24:872-876.
46. Herishanu Y., Perez-Gelen P., Liu D., Biancotto A., Vire B., Gibellini F., et al. Comparative gene expression profiling of leukemia cells in peripheral blood and tissue compartments reveals a prominent role of the microenvironment for CLL cell proliferation (abstract). Blood 2009, 114:355.
47. Muzio M., Apollonio B., Scielzo C., Frenquelli M., Vandoni I., Boussiotis V., et al. Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of anergy. Blood 2008, 112:188-195.
48. Zupo S., Massara R., Dono M., Rossi E., Malavasi F., Cosulich M.E., et al. Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. Blood 2000, 95:1199-1206.
49. Burger J.A., Quiroga M.P., Hartmann E., Burkle A., Wierda W.G., Keating M.J., et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood 2009, 113:3050-3058.
50. Quiroga M.P., Balakrishnan K., Kurtova A.V., Sivina M., Keating M.J., Wierda W.G., et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009, 114:1029-1037.
51. Kitada S., Andersen J., Akar S., Zapata J.M., Takayama S., Krajewski S., et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with In vitro and In vivo chemoresponses. Blood 1998, 91:3379-3389.
52. Hewamana S., Lin T.T., Rowntree C., Karunanithi K., Pratt G., Hills R., et al. Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. J Clin Oncol 2009, 27:763-769.
53. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., Efremov D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
54. Enders A., Bouillet P., Puthalakath H., Xu Y., Tarlinton D.M., Strasser A. Loss of the pro-apoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med 2003, 198:1119-1126.
55. Ewings K.E., Wiggins C.M., Cook S.J. Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels. Cell Cycle 2007, 6:2236-2240.
56. Iglesias-Serret D., De Frias M., Santidrian A.F., Coll-Mulet L., Cosialls A.M., Barragan M., et al. Regulation of the proapoptotic BH3-only protein BIM by glucocorticoids, survival signals and proteasome in chronic lymphocytic leukemia cells. Leukemia 2007, 21:281-287.
57. Zum Buschenfelde CM, Wagner M, Lutzny G, Oelsner M, Feuerstacke Y, Decker T, et al. Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. Leukemia 2010;24:141-52.
58. Pedersen I.M., Kitada S., Leoni L.M., Zapata J.M., Karras J.G., Tsukada N., et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood 2002, 100:1795-1801.
59. Pallasch C.P., Schulz A., Kutsch N., Schwamb J., Hagist S., Kashkar H., et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. Blood 2008, 112:4213-4219.
60. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
61. Bechter O.E., Eisterer W., Pall G., Hilbe W., Kuhr T., Thaler J. Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. Cancer Res 1998, 58:4918-4922.
62. Okada T., Cyster J.G. B cell migration and interactions in the early phase of antibody responses. Curr Opin Immunol 2006, 18:278-285.
63. Vlad A., Deglesne P.A., Letestu R., Saint-Georges S., Chevallier N., Baran-Marszak F., et al. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res 2009, 69:6387-6395.
64. Scielzo C., Ghia P., Conti A., Bachi A., Guida G., Geuna M., et al. HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. J Clin Invest 2005, 115:1644-1650.
65. Scielzo C., Bertilaccio M.T., Simonetti G., Dagklis A., Ten Hacken E., Fazi C., et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood 2010.
66. Arnold J.N., Wormald M.R., Suter D.M., Radcliffe C.M., Harvey D.J., Dwek R.A., et al. Human serum IgM glycosylation: identification of glycoforms that can bind to mannan-binding lectin. J Biol Chem 2005, 280:29080-29087.
67. Krysov S., Potter K.N., Mockridge C.I., Coelho V., Wheatley I., Packham G., et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood 2010, 115:4198-4205.
68. Vuillier F., Dumas G., Magnac C., Prevost M.C., Lalanne A.I., Oppezzo P., et al. Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. Blood 2005, 105:2933-2940.
69. Bell S.E., Goodnow C.C. A selective defect in IgM antigen receptor synthesis and transport causes loss of cell surface IgM expression on tolerant B lymphocytes. EMBO J 1994, 13:816-826.
70. Dennis J.W., Lau K.S., Demetriou M., Nabi I.R. Adaptive regulation at the cell surface by N-glycosylation. Traffic 2009, 10:1569-1578.
71. Bernasconi N.L., Onai N., Lanzavecchia A. A role for Toll-like receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood 2003, 101:4500-4504.
72. Radcliffe C.M., Arnold J.N., Suter D.M., Wormald M.R., Harvey D.J., Royle L., et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem 2007, 282:7405-7415.
73. Murphy L.O., Blenis J. MAPK signal specificity: the right place at the right time. Trends Biochem Sci 2006, 31:268-275.
74. Morabito F., Cutrona G., Gentile M., Fabbi M., Matis S., Colombo M., et al. Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL. Br J Haematol 2010, 149:160-163.
75. Contri A., Brunati A.M., Trentin L., Cabrelle A., Miorin M., Cesaro L., et al. Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. J Clin Invest 2005, 115:369-378.
76. Capitani N, Lucherini OM, Sozzi E, Ferro M, Giommoni N, Finetti F, et al. Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia. Blood 2010;115:3726-36.
77. Gabelloni M.L., Borge M., Galletti J., Canones C., Calotti P.F., Bezares R.F., et al. SHIP-1 protein level and phosphorylation status differs between CLL cells segregated by ZAP-70 expression. Br J Haematol 2008, 140:117-119.
78. Alfarano A., Indraccolo S., Circosta P., Minuzzo S., Vallario A., Zamarchi R., et al. An alternatively spliced form of CD79b gene may account for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999, 93:2327-2335.
79. Cragg M.S., Chan H.T., Fox M.D., Tutt A., Smith A., Oscier D.G., et al. The alternative transcript of CD79b is overexpressed in B-CLL and inhibits signaling for apoptosis. Blood 2002, 100:3068-3076.
80. Minuzzo S., Indraccolo S., Tosello V., Piovan E., Cabrelle A., Trentin L., et al. Heterogeneous intracellular expression of B-cell receptor components in B-cell chronic lymphocytic leukaemia (B-CLL) cells and effects of CD79b gene transfer on surface immunoglobulin levels in a B-CLL-derived cell line. Br J Haematol 2005, 130:878-889.
81. Chu D.H., Morita C.T., Weiss A. The Syk family of protein tyrosine kinases in T-cell activation and development. Immunol Rev 1998, 165:167-180.
82. Rosenwald A., Alizadeh A.A., Widhopf G., Simon R., Davis R.E., Yu X., et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001, 194:1639-1647.
83. Chen L., Apgar J., Huynh L., Dicker F., Giago-Mcgahan T., Rassenti L., et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005, 105:2036-2041.
84. Gobessi S., Laurenti L., Longo P.G., Sica S., Leone G., Efremov D.G. ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood 2007, 109:2032-2039.
85. Chen L., Huynh L., Apgar J., Tang L., Rassenti L., Weiss A., et al. ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood 2008, 111:2685-2692.
86. Richardson S.J., Matthews C., Catherwood M.A., Alexander H.D., Carey B.S., Farrugia J., et al. ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). Blood 2006, 107:3584-3592.
87. Herling M., Patel K.A., Weit N., Lilienthal N., Hallek M., Keating M.J., et al. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood 2009, 114:4675-4686.
88. Bichi R., Shinton S.A., Martin E.S., Koval A., Calin G.A., Cesari R., et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 2002, 99:6955-6960.
89. Venkataraman C., Chen X.C., Na S., Lee L., Neote K., Tan S.L. Selective role of PKCbeta enzymatic function in regulating cell survival mediated by B cell antigen receptor cross-linking. Immunol Lett 2006, 105:83-89.
90. Kang S.W., Wahl M.I., Chu J., Kitaura J., Kawakami Y., Kato R.M., et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J 2001, 20:5692-5702.
91. Abrams S.T., Lakum T., Lin K., Jones G.M., Treweeke A.T., Farahani M., et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood 2007, 109:1193-1201.
92. Meeker T.C., Lowder J., Maloney D.G., Miller R.A., Thielemans K., Warnke R., et al. A clinical trial of anti-idiotype therapy for B cell malignancy. Blood 1985, 65:1349-1363.
93. Savelyeva N., King C.A., Vitetta E.S., Stevenson F.K. Inhibition of a vaccine-induced anti-tumor B cell response by soluble protein antigen in the absence of continuing T cell help. Proc Natl Acad Sci USA 2005, 102:10987-10992.
94. Press O.W., Leonard J.P., Coiffier B., Levy R., Timmerman J. Immunotherapy of Non-Hodgkin's lymphomas. Hematology Am Soc Hematol Educ Program 2001, 221-240.
95. Buchner M., Fuchs S., Prinz G., Pfeifer D., Bartholome K., Burger M., et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009, 69:5424-5432.
96. Baudot A.D., Jeandel P.Y., Mouska X., Maurer U., Tartare-Deckert S., Raynaud S.D., et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene 2009, 28:3261-3273.
97. Gobessi S., Laurenti L., Longo P.G., Carsetti L., Berno V., Sica S., et al. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 2009, 23:686-697.
98. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578-85.
99. Buchner M., Baer C., Prinz G., Dierks C., Burger M., Zenz T., et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010, 115:4497-4506.
100. Amrein L., Hernandez T.A., Ferrario C., Johnston J., Gibson S.B., Panasci L., et al. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 2008, 143:698-706.
101. Hibbs M.L., Tarlinton D.M., Armes J., Grail D., Hodgson G., Maglitto R., et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995, 83:301-311.
102. Nishizumi H., Taniuchi I., Yamanashi Y., Kitamura D., Ilic D., Mori S., et al. Impaired proliferation of peripheral B cells and indication of autoimmune disease in lyn-deficient mice. Immunity 1995, 3:549-560.